[Molecular targeted therapies].
Current treatment paradigms in cancer patients are shifting from cytotoxic chemotherapies alone to single-agent and combination biological and targeted therapies. Targeted therapies are entering standard treatment paradigms. As patient responses to targeted therapies vary, predictive biomarkers will be an important tool of a patient's diagnostic workup in personalized medicine. This review provides a broad overview of molecular targeted agents, and highlight biomarkers, including novel adaptive clinical trial designs, incorporating putative biomarkers into prospective clinical trials.
Department of Genome Biology, Kinki University School of Medicine.
Hideharu
H
Kimura
Kazuto
K
Nishio
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000954:Antigens, Surface / Q000276:immunology; D000068258:Bevacizumab; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D000069283:Rituximab
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000954:Antigens, Surface; D014408:Biomarkers, Tumor; D004791:Enzyme Inhibitors; D000068258:Bevacizumab; D000069283:Rituximab; D011505:Protein-Tyrosine Kinases